Clearside Biomedical (CLSD) was downgraded to a Hold Rating at Chardan Capital
Clearside Biomedical received a Hold rating and price target from Chardan Capital analyst Daniil Gataulin yesterday. The company’s shares closed yesterday at $0.60. Elevate Your Investing Strategy: Gataulin covers the Healthcare sector, focusing on stocks …